Literature DB >> 11501987

Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.

A H Groll1, S C Piscitelli, T J Walsh.   

Abstract

The pharmacodynamics of antifungal compounds involve relationships among drug concentrations, time, and antimicrobial effects in vitro and in vivo. Beyond better understanding of a drug's mode of action, characterization of these relationships has important implications for setting susceptibility breakpoints, establishing rational dosing regimens, and facilitating drug development. Important advances have been made in the experimental investigation of pharmacokinetics and pharmacodynamics of antifungal drugs; however, much remains to be learned about specific pathogens and specific sites of infection. Increased incorporation of pharmacokinetic and pharmacodynamic principles in experimental and clinical studies with antifungal agents is an important objective that will benefit the treatment and prophylaxis of life-threatening invasive fungal infections in immunocompromised patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11501987     DOI: 10.1592/phco.21.12.133s.34507

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  19 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 2.  Pharmacokinetics of antifungal agents in children.

Authors:  Kevin Watt; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Early Hum Dev       Date:  2011-02-01       Impact factor: 2.079

Review 3.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

Review 4.  Pharmacokinetic/pharmacodynamic profile of posaconazole.

Authors:  Yanjun Li; Ursula Theuretzbacher; Cornelius J Clancy; M Hong Nguyen; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

Review 5.  Extended Dosing Regimens for Fungal Prophylaxis.

Authors:  Thomas Lehrnbecher; Konrad Bochennek; Thomas Klingebiel; Silke Gastine; Georg Hempel; Andreas H Groll
Journal:  Clin Microbiol Rev       Date:  2019-05-15       Impact factor: 26.132

6.  Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis.

Authors:  Andreas H Groll; Lauren Wood; Maureen Roden; Diana Mickiene; Christine C Chiou; Ellen Townley; Luqman Dad; Stephen C Piscitelli; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults.

Authors:  Rachel Courtney; Sudhakar Pai; Mark Laughlin; Josephine Lim; Vijay Batra
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

8.  Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.

Authors:  Susan M Abdel-Rahman; Richard F Jacobs; Joseph Massarella; Ralph E Kauffman; John S Bradley; Hui C Kimko; Gregory L Kearns; Kevin Shalayda; Christopher Curtin; Samuel D Maldonado; Jeffrey L Blumer
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

Review 9.  Antimicrobial dosing in acute renal replacement.

Authors:  William H Fissell
Journal:  Adv Chronic Kidney Dis       Date:  2013-01       Impact factor: 3.620

Review 10.  Pediatric antifungal agents.

Authors:  Michael Cohen-Wolkowiez; Cassandra Moran; Daniel K Benjamin; Phillip B Smith
Journal:  Curr Opin Infect Dis       Date:  2009-12       Impact factor: 4.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.